Will Gilead take over the hepatitis C market, too?
Gilead has attracted attention of the industry if it would continue the success of its domestic antivirus treatment even in the hepatitis C treatment market.
Recently, Gilead has actively established a hepatitis C product pipeline by acquiring ‘Harvoni(sofosbuvir+ledipasivir),’ a genotype 1 hepa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
